Stereotactic ablative radiotherapy tops for inoperable early NSCLC
Australian and New Zealand research confirms what clinicians suspected
Compared with standard radiotherapy, stereotactic ablative body radiotherapy (SABR) provides better local control and improved survival in patients with inoperable non-small-cell lung cancer (NSCLC), according to results of the CHISEL study.
“The findings of this trial suggest that SABR should be the treatment of choice for this patient group,” the study team concludes in The Lancet Oncology.
